ACLS THER |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 07-16 | Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly | MT |
| 07-05 | Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing | MT |
Chart calendar ACLS THER
a2ba8c6a2bebbf628c.MeuoeLMzg0EZTv7LJUK-_ZrTLRI2Vd0EPp3rCHgnAwo.AILpJ_h0xSoud62lQhaGjfjrYF1SG_A8U-msbjp0aVJeg8BA9QrEA2Mmvw~95545f68b8f78224e8e2710ab4521662
Upcoming events on ACLS THER
Past events on ACLS THER
| 11/06/2024 16:20 | Goldman Sachs Global Healthcare Conference |
| 06/06/2024 14:00 | Annual General Meeting |
| 07/05/2024 22:00 | Q1 2024 Earnings Call |
| 07/05/2024 21:01 | Q1 2024 Earnings Release |
| 27/02/2024 12:00 | Q4 2023 Earnings Release |
| 13/11/2023 13:00 | Zunsemetinib Phase IIb Rheumatoid Arthritis Trial Results Call |
| 06/11/2023 12:00 | Q3 2023 Earnings Release |
| 26/09/2023 15:30 | Cantor Global Healthcare Conference |
| 07/08/2023 12:00 | Q2 2023 Earnings Release |
| 15/06/2023 00:40 | Goldman Sachs Global Healthcare Conference |
| 08/06/2023 21:30 | Jefferies Global Healthcare Conference |
| 01/06/2023 14:00 | Annual General Meeting |
| 08/05/2023 13:00 | Q1 2023 Earnings Call |
| 08/05/2023 12:00 | Q1 2023 Earnings Release |
| 30/03/2023 18:00 | H.C. Wainwright Autoimmune & Inflammatory Disease Conference |
| 23/02/2023 12:00 | FY 2022 Earnings Release |
| 14/02/2023 14:20 | SVB Securities Global Biopharma Conference |
| 11/01/2023 22:15 | JP Morgan Healthcare Conference |
| 29/11/2022 14:30 | Piper Sandler Healthcare Conference |
| 16/11/2022 17:00 | Jefferies London Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 4,23 12,7 -66.79% | 6,48 6,29 2.97% | 6,76 7,05 -4.13% | 29,8 24,0 24% | 31,2 18,3 70.43% | 10,6 |
|
EBITDA Million USD | Released Forecast Spread | -86,1 -84,1 -2.37% | 0,00 0,00 - | 0,00 0,00 - | -89,1 -84,1 -5.84% | -96,5 -123 21.74% | -87,4 |
|
EBIT Million USD | Released Forecast Spread | -92,6 -120 22.96% | -50,9 -48,4 -5.08% | -89,7 -90,1 0.38% | -89,9 -91,7 2.05% | -97,4 -119 17.94% | -63,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -114 -129 12.29% | -51,3 -48,6 -5.7% | -90,9 -91,1 0.21% | -86,9 -91,0 4.51% | -88,8 -113 21.66% | -58,5 |
|
Net income Million USD | Released Forecast Spread | -161 -131 -23.07% | -51,0 -48,7 -4.83% | -90,9 -91,0 0.2% | -86,9 -90,5 3.94% | -88,5 -112 20.68% | -53,3 |
|
EPS USD | Released Forecast Spread | -3,90 -3,17 -22.9% | -1,20 -1,15 -4.05% | -1,60 -1,61 0.42% | -1,33 -1,46 8.98% | -1,27 -1,60 20.68% | -0,75 |
| Announcement Date | 25/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1,45 1,67 -12.74% | 1,53 1,61 -5.2% | 19,0 1,60 1085.34% | 7,75 1,99 288.82% | 2,53 1,75 44.6% | 1,87 1,90 -1.6% | 9,28 1,57 489.83% | 17,6 5,05 247.87% | 2,40 1,93 24.33% | 1,82 | 2,70 | 3,71 | 1,94 | 1,69 |
|
EBIT Million USD | Released Forecast Spread | -18,9 -24,6 23.11% | -21,0 -24,5 14.23% | -20,9 -26,5 21.34% | -29,1 -29,8 2.57% | -29,9 -29,1 -2.8% | -31,8 -31,8 -0.14% | -31,6 -34,3 7.92% | -4,05 -25,2 83.92% | -18,9 -14,3 -32.23% | -16,3 | -14,7 | -13,7 | -18,9 | -20,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -18,8 -24,6 23.56% | -20,5 -24,4 15.97% | -20,0 -26,9 25.86% | -27,6 -30,8 10.22% | -28,2 -29,0 2.75% | -29,6 -32,1 7.92% | -29,3 -34,3 14.77% | -1,86 -25,2 92.62% | -16,9 -20,4 16.8% | -14,3 | -13,7 | -13,6 | -23,9 | -24,1 |
|
Net income Million USD | Released Forecast Spread | -18,8 -24,8 24.29% | -20,5 -23,8 13.71% | -20,0 -26,3 24.16% | -27,6 -30,5 9.35% | -28,2 -29,2 3.62% | -29,6 -31,7 6.67% | -29,3 -33,9 13.81% | -1,49 -23,6 93.69% | -16,9 -20,3 16.64% | -13,5 | -12,0 | -10,9 | -19,4 | -19,7 |
|
EPS USD | Released Forecast Spread | -0,31 -0,40 23.14% | -0,31 -0,36 13.49% | -0,30 -0,40 24.19% | -0,41 -0,46 10.14% | -0,42 -0,44 4.55% | -0,42 -0,45 7.44% | -0,41 -0,48 14.81% | -0,02 -0,33 94.01% | -0,24 -0,27 11.11% | -0,19 | -0,17 | -0,15 | -0,22 | -0,22 |
| Announcement Date | 10/05/22 | 03/08/22 | 08/11/22 | 23/02/23 | 08/05/23 | 07/08/23 | 06/11/23 | 27/02/24 | 07/05/24 | - | - | - | - | - |
| 21/07/2024 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release |
| 22/07/2024 12:00 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release |
| 23/07/2024 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release |
| 23/07/2024 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
| 23/07/2024 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release |
| 24/07/2024 | LONZA GROUP AG: Q2 2024 Earnings Release |
| 25/07/2024 06:00 | BACHEM HOLDING AG: Q2 2024 Earnings Release |
| 25/07/2024 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
| 26/07/2024 06:00 | BB BIOTECH AG: Q2 2024 Earnings Release |
| 28/07/2024 | CRISPR THERAPEUTICS AG: Q2 2024 Earnings Release (Projected) |
Past sector events for ACLS THER
| 15/07/2024 06:45 | ADDLIFE AB: Q2 2024 Earnings Release |
| 10/07/2024 08:01 | SUNMAX BIOTECHNOLOGY CO., LTD.: June 2024 Sales and Revenue Release |
| 10/07/2024 06:51 | POLARIS GROUP: June 2024 Sales and Revenue Release |
| 11/06/2024 08:04 | SUNMAX BIOTECHNOLOGY CO., LTD.: May 2024 Sales and Revenue Release |
| 07/06/2024 07:57 | POLARIS GROUP: May 2024 Sales and Revenue Release |
| 29/05/2024 21:01 | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
| 23/05/2024 12:00 | CUREVAC N.V.: Q1 2024 Earnings Release |
| 22/05/2024 06:00 | EVOTEC SE: Q1 2024 Earnings Release |
| 21/05/2024 22:14 | ALVOTECH: Q1 2024 Earnings Release |
| 21/05/2024 12:00 | EXSCIENTIA PLC: Q1 2024 Earnings Release |
- Stock Market
- Equities
- ACRS Stock
- Stock
- Calendar ACLS THER